A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
These findings suggest specific parasite loci may be under vaccine-induced immune pressure and highlight potential targets for future optimization of whole-sporozoite vaccines. PfSPZ Vaccine development has been closely linked with malaria elimination efforts on Bioko Island, Equatorial Guinea. By 2024–2025, a series of registry studies, incidence surveys and dose-optimization trials had been completed as part of preparations for a large-scale, Africa-led phase 3 efficacy trial. These activities were coordinated through the Equatoguinean Malaria Vaccine Initiative, which aims to evaluate PfSPZ Vaccine in a setting with intense seasonal transmission and established malaria control programs.
Critics gave Darbar mixed reviews. On the review aggregator website Rotten Tomatoes, 50% of 8 critics' reviews are positive, with an average rating of 6.2/10. Sreedhar Pillai, writing for Firstpost gave Darbar a rating of two-and-tree-quarter stars out of five and stated "The first half of Darbar is enjoyable mainly due to Rajinikanth's style and swagger". Saibal Chatterjee of NDTV gave the film two-and-a-half stars out of five and wrote "Darbar is targeted fair and square at Rajinikanth fans, but it does nothing to give masala cinema a fresh shot of energy". Writing for The Times of India, M Suganth gave three stars out of five and stated "Darbar is an engaging commercial cocktail of action and drama". Shubhra Gupta, editor-in-chief of The Indian Express, gave two-and-a-half stars out of five and stated "Darbar remains a Rajinikanth film which bows at each step to the continuing myth of the one and only Thalaivar". S Srivatsan from The Hindu stated "Despite A.R. Murugadoss offering very little substance for him to work with, the superstar just about manages to carry this film on his aging shoulders". Sify gave two-and-a-half stars out of five and stated, "Darbar is an average cop action entertainer packed to satisfy the appetite of the die-hard fans of Thalaivar". Karthik Kumar of Hindustan Times wrote "AR Murugadoss plays on Rajinikanth's strength and swag, but everything else in this film gets a lackadaisical treatment". Baradwaj Rangan wrote for Film Companion, "The film falls in a no-man's land, where the drama and the action is neither powerful nor punchy enough".
=== Brand names === Metandienone was introduced and formerly sold primarily under the brand name Dianabol. It has also been marketed under a variety of other brand names including Anabol, Averbol, Chinlipan, Danabol, Dronabol, Metanabol, Methandon, Naposim, Reforvit-B, and Vetanabol among others.
Hart had a guest appearance in the 2002 sitcom, Undeclared. He made his film debut in the 2002 film Paper Soldiers. Hart then had other film roles such as the Scary Movie franchise, Soul Plane, The 40-Year-Old Virgin, Death at a Funeral and Little Fockers. He turned down a role in the 2008 film Tropic Thunder because the character is gay, citing his own "insecurities". He played Doug in the film The Five-Year Engagement (2012) and appeared in Think Like a Man which was a box office success. He also appeared in the sequel. He had a cameo as himself in This Is the End. In 2013, Hart played a boxing promoter in Grudge Match and appeared in Exit Strategy as Mannequin Head Man. He also appeared in 35 and Ticking. In 2013, Hart co-created Real Husbands of Hollywood with Chris Spencer. The show follows Hart along with other married celebrities (each playing a comical fictionalized version of themselves) within the series including: Boris Kodjoe, Nelly, Duane Martin, J. B. Smoove, Nick Cannon and Robin Thicke. Thicke did not return for the second season due to his music career, though Hart has stated that the door is open for him to return. The series is filmed in a style similar to Bravo's The Real Housewives. Episodes often hinge on the "real" Hart's desperately unsuccessful attempts to climb Hollywood's celebrity social ladder (which always backfire in humiliating ways), and the character's barely-hidden envy of his more successful celebrity friends. A sneak peek was shown as a segment during the 2012 BET Awards and the official promo was released in October 2012.
=== Selection by organisms === Organisms, such as molluscs and arthropods, have shown the ability to grow all three crystal polymorphs of calcium carbonate, mainly as protection (shells) and muscle attachments. Moreover, they exhibit a remarkable capability of phase selection over calcite and aragonite, and some organisms can switch between the two polymorphs. The ability of phase selection is usually attributed to the use of specific macromolecules or combinations of macromolecules by such organisms.
Sources: en.wikipedia.org
=== Thrombin-like === These include thrombin, tissue activating plasminogen and plasmin. They have been found to have roles in coagulation and digestion as well as in the pathophysiology of neurodegenerative disorders such as Alzheimer's and Parkinson's induced dementia. Many highly-toxic thrombin-like serine protease isoforms are found in snake venoms.
Indenture, also known as bonded labour or debt bondage, is a form of unfree labour in which a person works to pay off a debt by pledging themself as collateral. The services required to repay the debt, and their duration, may be undefined. Debt bondage can be passed on from generation to generation, with children required to pay off their progenitors' debt. Debt bondage is most prevalent in South Asia, and is the most widespread form of slavery today. Money marriage refers to a marriage where a child, usually a girl, is married off to settle debts owed by their parents. The Chukri system is a debt bondage system found in parts of Bengal where a woman or girl can be coerced into prostitution in order to pay off debts.
These merged in 1962 creating the ULS. In 1979 the society had 11,000 members in 11 states and Canada. Headquarters in Ligonier, Pennsylvania. Zivena Beneficial Society - Founded in 1891. Headquartered in Ligonier, Pennsylvania, since at least the late 1970s, but in the early 1920s headquartered in Braddock, Pennsylvania. Had 5,611 at the end of 1918. 7,277 members in 1927, 4,357 in 1965, and 2,500 in 1977. The national convention met quadrennially. Licensed to sell insurance in Illinois, New York, Ohio, and Pennsylvania. Sponsored scholarships, gave aid to aged and handicapped members, and donated to civic and charitable groups. Merged into Croatian Fraternal Union in 1995.
== In polymer physics == In some scientific areas such as polymer physics, one may consider a chain of points and links between consecutive points. If the points are sequentially numbered and located at positions r1, r2, r3, etc. then bond vectors are defined by u1=r2−r1, u2=r3−r2, and ui=ri+1−ri, more generally. This is the case for kinematic chains or amino acids in a protein structure. In these cases, one is often interested in the half-planes defined by three consecutive points, and the dihedral angle between two consecutive such half-planes. If u1, u2 and u3 are three consecutive bond vectors, the intersection of the half-planes is oriented, which allows defining a dihedral angle that belongs to the interval (−π, π]. This dihedral angle is defined by
Visa requirements for Mexican citizens are administrative entry restrictions by the authorities of other states placed on citizens of Mexico. As of 2026, Mexican citizens have visa-free or visa on arrival access to 157 countries and territories, ranking the Mexican passport 22nd in the world according to the Henley Passport Index.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.